金属协调介导的纳米乳液,用于全合一药物输送
Yeji Jeon1, Jun Woo Park1, Su Jin Lee1
1Department of Biomaterials Science (BK21 FOUR Program), College of Natural Resources and Life Science/Life and Industry Convergence Research Institute, Pusan National University, Miryang 50463, Republic of Korea.
ACS applied bio materials
|March 14, 2025
概括
这项研究引入了用于联合提供抗癌药物的新型纳米乳液,克服了传统聚合物载体的局限性. 这些纳米乳液在减少结合化疗的癌细胞活力方面表现出更强的疗效.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 材料科学 材料科学 材料科学
背景情况:
- 组合化疗提高了疗效,降低了耐药性,但与药物输送载体面临挑战.
- 现有的用于组合化疗的聚合物载体在合成上复杂,并且在多药封装方面效率低下.
- 使用聚合物纠实现不同极性的药物的高封装效率存在局限性.
研究的目的:
- 开发一种新的,高效的基于纳米乳液的药物递送系统,用于联合递送水友性和水性抗癌药物.
- 克服与聚合物药物载体相关的合成复杂性和低封装效率的局限性.
- 为了证明这些纳米乳液在协同组合癌症治疗中的潜力.
主要方法:
- 纳米乳液的制造,在油/水接口使用滴状乳液工艺,由金属-系坐标键稳定.
- 一种具有50-100纳米颗粒大小的合稳定乳液的配方,稳定3周.
- 在纳米乳液中同时封装水友性凝胺和疏水性帕克利塔塞尔.
主要成果:
- 开发的纳米乳液表现出合稳定性和50-100纳米的尺寸范围.
- 成功地同时封装了水友性 (gemcitabine) 和水性 (paclitaxel) 抗癌药物.
- 与单一药物治疗相比,双药纳米乳液治疗显著降低了癌细胞活力 (57.0 ± 0.0%) (gemcitabine: 84.0 ± 9.9%; 帕克利塔塞尔: 83.4 ± 7.2%).
结论:
- 金属 - 的坐标键使得能够创建稳定的纳米乳液,以有效地联合提供各种抗癌药物.
- 这种纳米乳液平台为复杂的聚合物载体提供了一个有希望的替代方案,用于组合化疗.
- 增强的细胞毒性证明了这些纳米乳液在协同治疗癌症方面的潜力.
相关概念视频
01:19Modified-Release Drug Delivery Systems: Overview
175
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
175
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
115
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
115